ABLYNX ANNOUNCES ITS BUSINESS UPDATE FOR THE FIRST NINE

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ABLYNX ANNOUNCES ITS BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2014

REGULATED INFORMATION

A period of good pipeline progress towards later stage clinical trials, a major alliance in the field of immuno-oncology and a strengthened financial position

GHENT, Belgium, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced its non-audited business update, summarising Ablynx's financial position for the first nine months of 2014, material events post 30 th September 2014 and the outlook for the rest of 2014 and 2015.

Operating highlights - third quarter-to-date

  • Preparations to start the Phase III study in mid-2015 with the anti-vWF Nanobody, caplacizumab, in patients with acquired TTP, are well underway following compelling Phase II clinical proof-of-concept results from the TITAN study announced in June. In addition, results from the post-hoc analysis of this study will be presented at the upcoming American Society of Haematology (ASH) meeting in San Francisco, USA, on 8 th December at 7am Pacific Standard Time (PST) (16h CET)
  • The Paediatric Investigation Plan (PIP) for the anti-RSV Nanobody, ALX-0171, was approved by the EMA and Ablynx is on track to treat the first infant in the Phase IIa study before the end of 2014
  • The Company announced results from a Phase I study of the subcutaneous administration of the anti-IL-6R Nanobody, ALX-0061, demonstrating more than 80% bioavailability. Ablynx is on track to start the next Phase II studies with the subcutaneous formulation of ALX-0061 in RA and SLE in 2015
  • Ablynx expanded its relationship with a leading Chinese pharmaceutical company, Eddingpharm, by granting them a license to develop and commercialise the anti-TNFa Nanobody, ozoralizumab, in mainland China, Hong Kong, Macao and Taiwan

      

Financial highlights - first nine months ending 30 th September 2014

  • Raised €41.7 million through a private placement of new shares
  • More than doubled revenues to €35.2 million (2013: €16.7 million)
  • Reduced the net loss for the period to €9.1 million (2013: €18.9 million)
  • Net operational cash burn well under control at €17.8 million (2013: €30.9 million)
  • Strong financial position with €221.5 million in cash, cash equivalents, restricted cash and short-term investments (2013: €63.0 million)
  • Launched Spotlight Options on the Derivatives Market of Euronext Brussels and Sponsored Level I ADRs on the OTC Market in the USA

      

Commenting on today's update, Dr Edwin Moses, CEO of Ablynx, said:

"I am pleased to report continued good progress during the past nine months across the entire business. It has been an exciting year as we have focussed on implementing our strategy to develop the Company into a clinical stage biopharmaceutical company with later-stage products. With caplacizumab, we now have a Phase III ready asset for which we have the necessary resources and expertise to further develop the product towards commercialisation. We are on track to start the Phase IIa study, in infants with an RSV infection, using our first inhaled Nanobody, ALX-0171, which has first-in-class potential. We continued to make encouraging progress with our partnered programmes and were successful in the signing of our second deal with Merck & Co, in the field of immune-oncology."

"We further strengthened our financial position through an oversubscribed private placement of new shares, raising €41.7 million, whilst continuing to focus on prudent cash management. We look forward to the rest of 2014 and continuing important developments throughout 2015."

Financial review

(€ million) First 9 months of 2014 First 9 months of 2013 % change
Revenues 35.2 16.7 111%
  R&D income 34.1 15.7 117%
  Grants 1.1 0.9 22%
Operating expenses (46.9) (36.2) 30%
  R&D (39.1) (29.7) 32%
  G&A (7.8) (6.4) 22%
Operating result (11.7) (19.5) 40%
Net financial result 2.6 0.6 333%
Net result (9.1) (18.9) 48%
Net operational cash burn (17.8) (30.9) 42%
Net cash inflow/(burn) 21.1 (0.2) --
Cash at 30 th September 221.5 (1) 63.0 (2) 252%
       (1)  including €2.0 million restricted cash
       (2)  including €2.3 million restricted cash

 

Revenues more than doubled to €35.2 million (2013: €16.7 million) mainly driven by higher FTE and recognised upfront payments from on-going collaborations. Operating expenses increased to €46.9 million (2013: €36.2 million) due primarily to higher external R&D costs. The net loss for the period reduced by more than 50% to €9.1 million (2013: €18.9 million).

Following the successful placement completed on 3 rd July 2014, the Company had a positive net cash inflow of €21.1 million for the first 9 months of 2014 and ended the period with €221.5 million in cash, cash equivalents, restricted cash and short-term investments.

Events after 30 th September 2014 and outlook for the remainder of 2014 and 2015

On 21 st October , Ablynx announced the issuance of an additional 12,500 common shares in exchange for €22,500, as the result of the exercise of warrants by some employees and consultants of the Company. As a result of this transaction, Ablynx now has 54,014,159 shares outstanding.

On 23 rd October , Ablynx announced positive results from the Phase I study of the subcutaneous formulation of its anti-IL-6R Nanobody, ALX-0061.  Bioavailability after subcutaneous administration was higher than 80% and there were no significant safety or tolerability signals observed.

As planned, Ablynx expects to start the first-in-infant Phase IIa study with the anti-RSV Nanobody, ALX-0171, before the end of 2014. Results from the Phase I study with the anti-vWF Nanobody, caplacizumab, to demonstrate bioequivalence between the lyophilised and liquid formulations of caplacizumab are also anticipated before year-end. On 8 th December 2014, Dr Peyvandi, Principal Investigator of the Phase II TITAN trial, will present results from the post-hoc analysis of this study at the ASH Annual Meeting. For the full year 2014, Ablynx reiterated its net cash burn guidance (excluding the proceeds from the private placement) to be in the in the range of €30-35 million.

In 2015, the Company anticipates various value enhancing events, including: potential proof-of-concept results from the Phase IIa study with ALX-0171 in RSV infected infants; the start of the Phase II studies with ALX-0061 in RA and SLE; the start of a Phase III study with caplacizumab in patients with acquired TTP; the start of multiple Phase I studies with partners; results from various technology feasibility studies across multiple applications and; milestone payments from on-going partnerships.

Financial calendar 2015

26 February - Full-year results 2014
30 April - Annual General Meeting
13 May - Q1 results 2015
27 August - Half-year results 2015
18 November - Q3 results 2015

Shareholders' clubs @ Ablynx (Dutch only)

The next shareholders' club at Ablynx will take place on 10 th December 2014 at 5.45pm CET. If you would like to attend, please contact us via investors@ablynx.com .

Glossary

IL-6R          receptor of interleukin-6 - a cytokine involved in a wide range of biological activities
EMA           European Medicines Agency
RA              rheumatoid arthritis
RSV           respiratory syncytial virus - virus that infects the respiratory tract, including the lungs
SLE            systemic lupus erythematosus
TTP            thrombotic thrombocytopenic purpura - rare disorder of the blood coagulation system that causes extensive microscopic thromboses in the small blood vessels throughout the body

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies® , proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations and significant partnerships with pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com .

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:   +44 203 709 5700
e:  ablynx@consilium-comms.com

pdf format of the press release http://hugin.info/137912/R/1870863/658054.pdf

HUG#1870863

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 72

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 72

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 135

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 69

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 95

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 34

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 93

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 46

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 38

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Bond Fund Faces Investigation for Misconduct

Updated Category News Views 327

Investigation of Easterly ROCMuni High Income Bond Fund Investors of the Easterly ROCMuni High Income Municipal Bond Fund are facing troubling times. Recently, the Portnoy Law Firm initiated an investigation regarding potential securities fraud associated with this investment vehicle. If you have lost money after investing in the Easterly ROCMuni High Income, it's...

Continue Reading
Japan's Economic Transformation: Unleashing Investment Potential

Updated Category News Views 271

Understanding the Shift in Japanese Equities Japanese equities are experiencing a resurgence, and this transformation is hard to ignore. The landscape of investment in Japan is shifting rapidly, and for those keeping an eye on the developments, there are compelling reasons to be optimistic. For years, conventional thought had deemed Japan as a country facing overwhelming...

Continue Reading
Pet Grooming Services Market Growth Driven by Humanization Trends

Updated Category News Views 129

Exploring the Pet Grooming Services Market Growth The pet grooming services market is witnessing a remarkable transformation, with anticipated growth projected to reach over USD 12.05 billion during the next decade. The rising phenomenon of pet ownership, coupled with the ongoing trend of humanization, is significantly influencing this expansion. The global market was...

Continue Reading
Investors Unite Against Dow Inc. in Class Action Suit

Updated Category News Views 181

Class Action Lawsuit Filed Against Dow Inc. Pomerantz LLP has announced the filing of a significant class action lawsuit against Dow Inc. (NYSE: DOW) and certain high-ranking officials within the company. This legal move signals a definitive call to action for investors who may have been adversely affected by the company’s alleged misrepresentations and omissions...

Continue Reading
Innovative Philanthropy: A New Challenge for MrBeast

Updated Category News Views 505

Revolutionizing Philanthropy: A New Challenge for MrBeast In an exciting initiative that aims to transform the landscape of modern philanthropy, the 144K Collective has reached out to the well-known YouTube personality and philanthropy leader Jimmy Donaldson, popularly known as MrBeast. This event, titled "144K Vs. The Beast," represents a novel approach to enhancing...

Continue Reading